Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
1.5800 x 40 1.6100 x 30
Post-market by (Cboe BZX)
1.6100 -0.0600 (-3.59%) 03/28/25 [NASDAQ]
1.5800 x 40 1.6100 x 30
Post-market 1.6100 unch (unch) 19:16 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.5500
Day High
1.6500
Open 1.6300
Previous Close 1.6700 1.6700
Volume 1,266,900 1,266,900
Avg Vol 8,227,700 8,227,700
Stochastic %K 5.68% 5.68%
Weighted Alpha -73.52 -73.52
5-Day Change -0.1700 (-9.55%) -0.1700 (-9.55%)
52-Week Range 1.5450 - 7.6600 1.5450 - 7.6600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,226
  • Shares Outstanding, K 56,662
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,680 K
  • EBIT $ -79 M
  • EBITDA $ -78 M
  • 60-Month Beta 2.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.08

Options Overview Details

View History
  • Implied Volatility 172.76% ( +11.76%)
  • Historical Volatility 71.99%
  • IV Percentile 79%
  • IV Rank 29.67%
  • IV High 412.53% on 03/04/25
  • IV Low 71.60% on 12/12/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 58
  • Volume Avg (30-Day) 660
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 5,935
  • Open Int (30-Day) 4,848

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.10
  • Number of Estimates 6
  • High Estimate 0.93
  • Low Estimate -0.41
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +128.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5450 +4.21%
on 03/27/25
Period Open: 2.0100
2.7800 -42.09%
on 03/19/25
-0.4000 (-19.90%)
since 02/28/25
3-Month
1.5450 +4.21%
on 03/27/25
Period Open: 2.1900
2.8200 -42.91%
on 01/31/25
-0.5800 (-26.48%)
since 12/27/24
52-Week
1.5450 +4.21%
on 03/27/25
Period Open: 5.0700
7.6600 -78.98%
on 05/06/24
-3.4600 (-68.24%)
since 03/28/24

Most Recent Stories

More News
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.

BDTX : 1.6100 (-3.59%)
VTI : 273.43 (-1.99%)
IWM : 200.45 (-2.03%)
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

BDTX : 1.6100 (-3.59%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

BDTX : 1.6100 (-3.59%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

BDTX : 1.6100 (-3.59%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q1 Earnings Snapshot

Black Diamond: Q1 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Stocks Set to Open Lower as Investors Await U.S. Inflation Data and Big Bank Earnings, Chinese Inflation Data Disappoints

September S&P 500 futures (ESU23) are down -0.04%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.05% this morning as weak inflation data from China added to a gloomy global economic outlook...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
LEVI : 15.69 (-1.81%)
COST : 929.66 (-0.97%)
ZION : 49.47 (-1.57%)
CMA : 58.72 (-1.49%)
JPM : 242.85 (-2.12%)
WFC : 70.69 (-2.20%)
C : 70.33 (-2.12%)
BAYN.D.DX : 22.640 (-0.15%)
BDTX : 1.6100 (-3.59%)
SCHW : 77.81 (-2.25%)
Why Shares of Black Diamond Therapeutics Skyrocketed This Week

The company announced positive early-trial news for non-small cell lung cancer.

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM

Black Diamond Therapeutics has announced encouraging initial data from a Phase 1 study of BDTX-1535, an investigational fourth-generation EGFR MasterKey

BDTX : 1.6100 (-3.59%)
Black Diamond: Q1 Earnings Snapshot

Black Diamond: Q1 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical OfficerAdvanced MasterKey therapy pipeline with first...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer

- Dr. Yurasov brings over 25 years of experience in oncology drug development and regulatory expertise - CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 ...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine - ...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

 – Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts –  – Company...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

- Clinical update expected in second half of 2023 - CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc....

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company...

BDTX : 1.6100 (-3.59%)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and NSCLC including those with CNS metastasesPreclinical data...

BDTX : 1.6100 (-3.59%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 1.7567
2nd Resistance Point 1.7033
1st Resistance Point 1.6567
Last Price 1.6100
1st Support Level 1.5567
2nd Support Level 1.5033
3rd Support Level 1.4567

See More

52-Week High 7.6600
Fibonacci 61.8% 5.3241
Fibonacci 50% 4.6025
Fibonacci 38.2% 3.8809
Last Price 1.6100
52-Week Low 1.5450

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies